JP2011523647A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011523647A5 JP2011523647A5 JP2011510798A JP2011510798A JP2011523647A5 JP 2011523647 A5 JP2011523647 A5 JP 2011523647A5 JP 2011510798 A JP2011510798 A JP 2011510798A JP 2011510798 A JP2011510798 A JP 2011510798A JP 2011523647 A5 JP2011523647 A5 JP 2011523647A5
- Authority
- JP
- Japan
- Prior art keywords
- optionally substituted
- alkyl
- ring members
- compound
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims description 45
- 125000000623 heterocyclic group Chemical group 0.000 claims description 30
- 239000008194 pharmaceutical composition Substances 0.000 claims description 29
- 125000000217 alkyl group Chemical group 0.000 claims description 28
- 125000004404 heteroalkyl group Chemical group 0.000 claims description 28
- 125000001424 substituent group Chemical group 0.000 claims description 27
- 125000003342 alkenyl group Chemical group 0.000 claims description 25
- 125000000304 alkynyl group Chemical group 0.000 claims description 25
- 125000005843 halogen group Chemical group 0.000 claims description 20
- 150000003839 salts Chemical class 0.000 claims description 15
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 14
- 125000001072 heteroaryl group Chemical group 0.000 claims description 13
- 125000003118 aryl group Chemical group 0.000 claims description 10
- 230000000694 effects Effects 0.000 claims description 10
- 125000004122 cyclic group Chemical group 0.000 claims description 9
- -1 difluoromethoxy, trifluoromethoxy, methylsulfonyl Chemical group 0.000 claims description 9
- 208000002193 Pain Diseases 0.000 claims description 8
- 229910052799 carbon Inorganic materials 0.000 claims description 8
- 125000004432 carbon atom Chemical group C* 0.000 claims description 8
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 7
- 206010015037 epilepsy Diseases 0.000 claims description 6
- 125000000547 substituted alkyl group Chemical group 0.000 claims description 6
- 108090000312 Calcium Channels Proteins 0.000 claims description 5
- 102000003922 Calcium Channels Human genes 0.000 claims description 5
- 208000008589 Obesity Diseases 0.000 claims description 5
- 102000003691 T-Type Calcium Channels Human genes 0.000 claims description 5
- 108090000030 T-Type Calcium Channels Proteins 0.000 claims description 5
- 125000004450 alkenylene group Chemical group 0.000 claims description 5
- 125000002947 alkylene group Chemical group 0.000 claims description 5
- 125000004474 heteroalkylene group Chemical group 0.000 claims description 5
- 239000000203 mixture Substances 0.000 claims description 5
- 235000020824 obesity Nutrition 0.000 claims description 5
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 4
- 208000000094 Chronic Pain Diseases 0.000 claims description 4
- 208000005298 acute pain Diseases 0.000 claims description 4
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 claims description 4
- 230000001684 chronic effect Effects 0.000 claims description 4
- 125000002883 imidazolyl group Chemical group 0.000 claims description 4
- 125000001041 indolyl group Chemical group 0.000 claims description 4
- 125000000842 isoxazolyl group Chemical group 0.000 claims description 4
- 125000003226 pyrazolyl group Chemical group 0.000 claims description 4
- 125000004076 pyridyl group Chemical group 0.000 claims description 4
- 125000000335 thiazolyl group Chemical group 0.000 claims description 4
- 125000001544 thienyl group Chemical group 0.000 claims description 4
- 125000001246 bromo group Chemical group Br* 0.000 claims description 3
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 3
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 3
- 125000001153 fluoro group Chemical group F* 0.000 claims description 3
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims description 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 3
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 3
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 3
- 206010058019 Cancer Pain Diseases 0.000 claims description 2
- 206010020853 Hypertonic bladder Diseases 0.000 claims description 2
- 206010028980 Neoplasm Diseases 0.000 claims description 2
- 208000009722 Overactive Urinary Bladder Diseases 0.000 claims description 2
- 208000018737 Parkinson disease Diseases 0.000 claims description 2
- 208000028017 Psychotic disease Diseases 0.000 claims description 2
- 230000033228 biological regulation Effects 0.000 claims description 2
- 201000011510 cancer Diseases 0.000 claims description 2
- 206010012601 diabetes mellitus Diseases 0.000 claims description 2
- 230000035558 fertility Effects 0.000 claims description 2
- 208000017169 kidney disease Diseases 0.000 claims description 2
- 230000004112 neuroprotection Effects 0.000 claims description 2
- 208000020629 overactive bladder Diseases 0.000 claims description 2
- 208000019116 sleep disease Diseases 0.000 claims description 2
- 239000002552 dosage form Substances 0.000 claims 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 3
- 125000003107 substituted aryl group Chemical group 0.000 description 3
- 0 *c1cc(C(NCC2CCN(*)CC2)=O)cc(*)c1 Chemical compound *c1cc(C(NCC2CCN(*)CC2)=O)cc(*)c1 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 208000020685 sleep-wake disease Diseases 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US5817908P | 2008-06-02 | 2008-06-02 | |
| US5818508P | 2008-06-02 | 2008-06-02 | |
| US61/058,179 | 2008-06-02 | ||
| US61/058,185 | 2008-06-02 | ||
| US12/420,793 | 2009-04-08 | ||
| US12/420,793 US8377968B2 (en) | 2008-06-02 | 2009-04-08 | N-piperidinyl acetamide derivatives as calcium channel blockers |
| PCT/CA2009/000768 WO2009146540A1 (en) | 2008-06-02 | 2009-06-02 | N-piperidinyl acetamide derivatives as calcium channel blockers |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2011523647A JP2011523647A (ja) | 2011-08-18 |
| JP2011523647A5 true JP2011523647A5 (https=) | 2012-07-19 |
| JP5560264B2 JP5560264B2 (ja) | 2014-07-23 |
Family
ID=41380590
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011510798A Active JP5560264B2 (ja) | 2008-06-02 | 2009-06-02 | カルシウムチャネルブロッカーとしてのｎ−ピペリジニルアセトアミド誘導体 |
Country Status (16)
| Country | Link |
|---|---|
| US (4) | US8377968B2 (https=) |
| EP (2) | EP3189839B1 (https=) |
| JP (1) | JP5560264B2 (https=) |
| KR (3) | KR101722898B1 (https=) |
| CN (1) | CN102695506B (https=) |
| AU (1) | AU2009253797B2 (https=) |
| BR (1) | BRPI0915295B1 (https=) |
| CA (1) | CA2725355C (https=) |
| CY (1) | CY1123466T1 (https=) |
| ES (1) | ES2677911T3 (https=) |
| HR (1) | HRP20201243T1 (https=) |
| IL (2) | IL209581A (https=) |
| MX (1) | MX2010013208A (https=) |
| PL (1) | PL3189839T3 (https=) |
| WO (1) | WO2009146540A1 (https=) |
| ZA (1) | ZA201008838B (https=) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8362021B2 (en) * | 2006-05-11 | 2013-01-29 | Zalicus Pharmaceuticals Ltd. | Method for increasing the bioavailability of benzhydryl piperazine containing compounds |
| AU2010291834A1 (en) * | 2009-09-04 | 2012-03-15 | Zalicus Pharmaceuticals Ltd. | Substituted heterocyclic derivatives for the treatment of pain and epilepsy |
| US20120220564A1 (en) * | 2009-09-18 | 2012-08-30 | Zalicus Pharmaceuticals Ltd. | Selective calcium channel modulators |
| US8591944B2 (en) | 2011-03-08 | 2013-11-26 | Zalicus Pharmaceuticals Ltd. | Solid dispersion formulations and methods of use thereof |
| US8409560B2 (en) | 2011-03-08 | 2013-04-02 | Zalicus Pharmaceuticals Ltd. | Solid dispersion formulations and methods of use thereof |
| EP2567959B1 (en) | 2011-09-12 | 2014-04-16 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| AU2013224302B2 (en) * | 2012-02-21 | 2017-03-30 | Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.P.A. | 1H-indazole-3-carboxamide compounds as glycogen synthase kinase 3 beta inhibitors |
| JP6304492B2 (ja) | 2012-03-30 | 2018-04-04 | 日産化学工業株式会社 | トリアジノン化合物及びｔ型カルシウムチャネル阻害剤 |
| EP2961403A4 (en) | 2013-03-01 | 2016-11-30 | Zalicus Pharmaceuticals Ltd | HETEROCYCLIC INHIBITORS OF SODIUM CHANNEL |
| JPWO2015050212A1 (ja) | 2013-10-02 | 2017-03-09 | 日産化学工業株式会社 | Ｔ型カルシウムチャネル阻害剤 |
| EP3085695A1 (en) | 2013-12-17 | 2016-10-26 | Nissan Chemical Industries, Ltd. | Substituted triazinone compound and t-type calcium channel inhibitor |
| DK3364993T3 (da) | 2015-10-22 | 2023-01-09 | Cavion Inc | Fremgangsmåder til behandling af angelman syndrom |
| EP3340988B1 (en) | 2015-11-12 | 2025-04-09 | Afasci, Inc. | Ion channel inhibitory compounds, pharmaceutical formulations and uses |
| WO2018118101A1 (en) * | 2016-12-21 | 2018-06-28 | Praxis Precision Medicines, Inc. | T-type calcium channel modulators and methods of use thereof |
| CN110545806A (zh) | 2017-02-15 | 2019-12-06 | 卡维昂公司 | 钙通道抑制剂 |
| CN110770221B (zh) | 2017-04-26 | 2023-09-08 | 卡维昂公司 | 用于改善记忆和认知以及用于治疗记忆和认知障碍的方法 |
| EP3615010B1 (en) * | 2017-04-26 | 2024-08-21 | Cavion, Inc. | Methods for treating dravet syndrome |
| TWI879741B (zh) | 2018-10-03 | 2025-04-11 | 美商卡凡恩公司 | 以(r)-2-(4-異丙基苯基)-n-(1-(5-(2,2,2-三氟乙氧基)吡啶-2-基)乙基)乙醯胺治療自發性震顫 |
| EP3996746A4 (en) * | 2019-07-11 | 2023-08-23 | Praxis Precision Medicines, Inc. | T-TYPE CALCIUM CHANNEL MODULATOR FORMULATIONS AND METHODS OF USE THEREOF |
| IL297642A (en) * | 2020-04-29 | 2022-12-01 | Praxis Prec Medicines Inc | Methods for using t-type calcium channel modulators |
| US20240025852A1 (en) * | 2020-11-09 | 2024-01-25 | Praxis Precision Medicines, Inc. | T-type calcium channel modulators and methods of use thereof |
| CN116669724A (zh) * | 2020-11-09 | 2023-08-29 | 普拉西斯精密医药公司 | T型钙通道调节剂和其使用方法 |
| EP4329751A4 (en) * | 2021-04-26 | 2025-03-19 | Praxis Precision Medicines, Inc. | Methods of treatment with neuroactive steroids |
| CN114518425B (zh) * | 2022-02-11 | 2023-03-10 | 中国科学技术大学 | 同时检测单个免疫细胞胞浆和细胞膜的代谢物的分析方法 |
| EP4504170A4 (en) * | 2022-04-01 | 2026-04-08 | Praxis Prec Medicines Inc | T-TYPE CALCIUM CHANNEL MODULATORS COMPRISING A DIAZASPIROHEPTANE CORE AND THEIR METHODS OF USE |
| WO2023192665A2 (en) * | 2022-04-01 | 2023-10-05 | Praxis Precision Medicines, Inc. | T-type calcium channel modulators and methods of use thereof |
| AU2023245572A1 (en) * | 2022-04-01 | 2024-10-17 | Praxis Precision Medicines, Inc. | T-type calcium channel modulators comprising an azaspirononane core and methods of use thereof |
| US20250295646A1 (en) * | 2022-05-09 | 2025-09-25 | Praxis Precision Medicines, Inc. | Methods of use of t-type calcium channel modulators |
| KR20250165616A (ko) * | 2023-03-02 | 2025-11-26 | 프락시스 프리시젼 메디신즈, 인크. | 고함량 단일 투여 단위 제형 및 이의 사용 방법 |
| JP2026507197A (ja) * | 2023-03-02 | 2026-02-27 | プラクシス プレシジョン メディシンズ， インコーポレイテッド | 本態性振戦の治療方法 |
| WO2025188619A1 (en) * | 2024-03-04 | 2025-09-12 | Praxis Precision Medicines, Inc. | Methods of treating parkinson's disease with t-type calcium channel modulators |
| WO2025255502A1 (en) | 2024-06-07 | 2025-12-11 | Cavion, Inc. | PYRIDYL AMIDE Cav3 CHANNEL MODULATORS |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5852014A (en) | 1992-03-12 | 1998-12-22 | Smithkline Beecham P.L.C. | Condensed indole derivatives as 5HT4 -receptor antagonists |
| US5624677A (en) | 1995-06-13 | 1997-04-29 | Pentech Pharmaceuticals, Inc. | Controlled release of drugs delivered by sublingual or buccal administration |
| JPH11513382A (ja) * | 1995-10-20 | 1999-11-16 | ドクトル カルル トーマエ ゲゼルシャフト ミット ベシュレンクテル ハフツング | ５員複素環化合物、これらの化合物を含む医薬品、それらの使用及びそれらの調製方法 |
| IT1291569B1 (it) | 1997-04-15 | 1999-01-11 | Angelini Ricerche Spa | Indazolammidi come agenti serotoninergici |
| IL125658A0 (en) | 1997-08-18 | 1999-04-11 | Hoffmann La Roche | Ccr-3 receptor antagonists |
| FR2769914B1 (fr) | 1997-10-21 | 2000-02-04 | Synthelabo | Derives d'indazole tricycliques leur preparation et leur application en therapeutique |
| US20030125269A1 (en) | 1998-08-26 | 2003-07-03 | Ming Li | T-type calcium channel |
| TW570920B (en) | 1998-12-22 | 2004-01-11 | Janssen Pharmaceutica Nv | 4-(aminomethyl)-piperidine benzamides for treating gastrointestinal disorders |
| GR20000100283A (el) * | 2000-08-17 | 2002-05-24 | Κωνσταντινος Αλεξοπουλος | Μη-πεπτιδικοι μιμητες της δραστικης αλληλουχιας s42fllr46 του υποδοχεα της θρομβινης για την θεραπεια της θρομβωσης και του καρκινου |
| EP1217000A1 (en) | 2000-12-23 | 2002-06-26 | Aventis Pharma Deutschland GmbH | Inhibitors of factor Xa and factor VIIa |
| CA2443108A1 (en) | 2001-04-03 | 2002-10-17 | Merck & Co. Inc. | N-substituted nonaryl-heterocyclo amidyl nmda/nr2b antagonists |
| WO2003007953A1 (en) | 2001-07-18 | 2003-01-30 | Washington University | Methods and compositions for modulating t-type calcium channels |
| KR100534556B1 (ko) | 2001-10-26 | 2005-12-08 | 주식회사 오리엔트바이오 | 알파１ｇ 단백질의 기능을 억제하여 간질을 일으키지 않게하는 방법 |
| KR20030037081A (ko) | 2001-11-02 | 2003-05-12 | 한국과학기술연구원 | Ｔ 타입 칼슘채널을 조절하여 복통을 억제하는 방법 |
| GB0126781D0 (en) | 2001-11-07 | 2002-01-02 | Medical Res Council | Modulation |
| DE10227511A1 (de) | 2002-06-19 | 2004-01-08 | Max-Delbrück-Centrum für Molekulare Medizin | Mittel zur medikamentösen Behandlung von akuten und chronischen Schmerzen |
| WO2004035000A2 (en) | 2002-10-17 | 2004-04-29 | Merck & Co., Inc. | Enhancement of sleep with t-type calcium channel antagonists |
| WO2004046110A1 (ja) | 2002-11-15 | 2004-06-03 | Yamanouchi Pharmaceutical Co., Ltd. | メラニン凝集ホルモン受容体拮抗剤 |
| EP1583821A4 (en) | 2003-01-15 | 2007-07-18 | Millennium Pharm Inc | METHODS AND COMPOSITIONS FOR TREATING UROLOGICAL DISORDERS USING GENES 44390, 54181, 211, 5687, 884, 1405, 636, 4421, 5410, 30905, 2045, 16405, 18560, 2047, 33751, 52872, 14063, 20739, 32544, 43239, 44373, 51164, 53010, 16852, 1587, 2207, 22245, 2387, 52908, 69112, 14990, 18547, 115, 579 |
| WO2004105750A1 (en) | 2003-05-30 | 2004-12-09 | Neuromed Technologies, Inc. | 3-aminomethyl-pyrrolidines as n-type calcium channel blockers |
| US7507760B2 (en) | 2004-01-22 | 2009-03-24 | Neuromed Pharmaceuticals Ltd. | N-type calcium channel blockers |
| JP2008501633A (ja) | 2004-02-11 | 2008-01-24 | ユニバーシティ オブ ヴァージニア パテント ファウンデーション | 癌の診断及び治療のためのＣａｖ３アイソフォーム及びそのδ２５スプライスバリアントの阻害 |
| WO2005092882A1 (en) | 2004-03-01 | 2005-10-06 | Pfizer Japan, Inc. | 4-amino-5-halogeno-benzamide derivatives as 5-ht4 receptor agonists for the treatment of gastrointestinal, cns, neurological and cardiovascular disorders |
| US20060003020A1 (en) | 2004-03-11 | 2006-01-05 | The Regents Of The University Of Michigan | Anti-metastatic ability of mibefradil and gadolinium |
| US7888374B2 (en) * | 2005-01-28 | 2011-02-15 | Abbott Laboratories | Inhibitors of c-jun N-terminal kinases |
| US20100222387A1 (en) | 2005-06-23 | 2010-09-02 | Barrow James C | 3-Fluoro-Piperidine T-Type Calcium Channel Antagonists |
| JP2009500340A (ja) | 2005-06-29 | 2009-01-08 | メルク エンド カムパニー インコーポレーテッド | ４−フルオロ−ピペリジンｔ型カルシウムチャネルアンタゴニスト |
| EP1943215A2 (en) | 2005-10-31 | 2008-07-16 | Brystol-Myers Squibb Company | Pyrrolidinyl beta-amino amide-based inhibitors of dipeptidyl peptidase iv and methods |
| CA2669736C (en) * | 2005-11-03 | 2017-02-21 | Chembridge Research Laboratories, Inc. | Heterocyclic compounds as tyrosine kinase modulators |
| UA96283C2 (uk) | 2005-12-23 | 2011-10-25 | Зіланд Фарма А/С | Модифіковані міметики лізину |
| US20090156465A1 (en) | 2005-12-30 | 2009-06-18 | Sattigeri Jitendra A | Derivatives of beta-amino acid as dipeptidyl peptidase-iv inhibitors |
| CA2663280A1 (en) | 2006-09-14 | 2008-03-20 | Neuromed Pharmaceuticals Ltd. | Diaryl piperidine compounds as calcium channel blockers |
| US20090298834A1 (en) | 2008-06-02 | 2009-12-03 | Hassan Pajouhesh | 4-(aminomethyl)cyclohexanamine derivatives as calcium channel blockers |
| US20120220564A1 (en) | 2009-09-18 | 2012-08-30 | Zalicus Pharmaceuticals Ltd. | Selective calcium channel modulators |
-
2009
- 2009-04-08 US US12/420,793 patent/US8377968B2/en active Active
- 2009-06-02 BR BRPI0915295-4A patent/BRPI0915295B1/pt active IP Right Grant
- 2009-06-02 KR KR1020167032345A patent/KR101722898B1/ko active Active
- 2009-06-02 KR KR1020107028775A patent/KR101909749B1/ko active Active
- 2009-06-02 EP EP17155716.8A patent/EP3189839B1/en active Active
- 2009-06-02 JP JP2011510798A patent/JP5560264B2/ja active Active
- 2009-06-02 AU AU2009253797A patent/AU2009253797B2/en active Active
- 2009-06-02 EP EP09757002.2A patent/EP2300007B1/en active Active
- 2009-06-02 MX MX2010013208A patent/MX2010013208A/es unknown
- 2009-06-02 WO PCT/CA2009/000768 patent/WO2009146540A1/en not_active Ceased
- 2009-06-02 ES ES09757002.2T patent/ES2677911T3/es active Active
- 2009-06-02 KR KR1020187029396A patent/KR20180115346A/ko not_active Ceased
- 2009-06-02 CA CA2725355A patent/CA2725355C/en active Active
- 2009-06-02 CN CN200980129679.1A patent/CN102695506B/zh active Active
- 2009-06-02 PL PL17155716T patent/PL3189839T3/pl unknown
-
2010
- 2010-11-25 IL IL209581A patent/IL209581A/en active IP Right Grant
- 2010-12-08 ZA ZA2010/08838A patent/ZA201008838B/en unknown
-
2012
- 2012-08-31 US US13/601,357 patent/US8569344B2/en active Active
-
2013
- 2013-08-29 US US14/013,934 patent/US9096522B2/en active Active
-
2015
- 2015-06-29 US US14/753,936 patent/US20160175315A1/en not_active Abandoned
-
2017
- 2017-03-20 IL IL251281A patent/IL251281B/en active IP Right Grant
-
2020
- 2020-08-07 HR HRP20201243TT patent/HRP20201243T1/hr unknown
- 2020-08-14 CY CY20201100761T patent/CY1123466T1/el unknown